BR112019023869A2 - variantes de sulfamidase (sgsh), vetores, composições e métodos e usos para tratar mucopolissacaridose tipo iiia (mps iiia) - Google Patents
variantes de sulfamidase (sgsh), vetores, composições e métodos e usos para tratar mucopolissacaridose tipo iiia (mps iiia) Download PDFInfo
- Publication number
- BR112019023869A2 BR112019023869A2 BR112019023869A BR112019023869A BR112019023869A2 BR 112019023869 A2 BR112019023869 A2 BR 112019023869A2 BR 112019023869 A BR112019023869 A BR 112019023869A BR 112019023869 A BR112019023869 A BR 112019023869A BR 112019023869 A2 BR112019023869 A2 BR 112019023869A2
- Authority
- BR
- Brazil
- Prior art keywords
- sgsh
- iiia
- variants
- sulfamidase
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505423P | 2017-05-12 | 2017-05-12 | |
| PCT/US2018/032454 WO2018209317A1 (en) | 2017-05-12 | 2018-05-11 | Sulfamidase (sgsh) variants, vectors, compositions and methods and uses for treating mucopolysaccharidosis type iiia (mps iiia) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023869A2 true BR112019023869A2 (pt) | 2020-06-09 |
Family
ID=64104969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023869A BR112019023869A2 (pt) | 2017-05-12 | 2018-05-11 | variantes de sulfamidase (sgsh), vetores, composições e métodos e usos para tratar mucopolissacaridose tipo iiia (mps iiia) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12221635B2 (https=) |
| EP (1) | EP3622060A4 (https=) |
| JP (1) | JP7196099B2 (https=) |
| CN (1) | CN110809626A (https=) |
| AU (1) | AU2018265869C1 (https=) |
| BR (1) | BR112019023869A2 (https=) |
| CA (1) | CA3061925A1 (https=) |
| MX (1) | MX2019013528A (https=) |
| RU (1) | RU2019140862A (https=) |
| WO (1) | WO2018209317A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108728495A (zh) * | 2018-05-31 | 2018-11-02 | 深圳市免疫基因治疗研究院 | 一种Sanfilippo A综合症慢病毒载体、慢病毒及其制备方法和应用 |
| WO2020127678A1 (en) * | 2018-12-20 | 2020-06-25 | Esteve Pharmaceuticals, S.A. | Recombinant vectors for the long term treatment of mucchopolysacharidosis |
| EP3999647A1 (en) * | 2019-07-18 | 2022-05-25 | Lysogene | Compositions and methods for the treatment of sanfilippo disease and other disorders |
| PH12022551247A1 (en) * | 2019-11-22 | 2023-11-13 | Childrens Hospital Philadelphia | Adeno-associated viral vector variants |
| JP2023517230A (ja) * | 2020-03-11 | 2023-04-24 | リモーター セラピューティクス インコーポレイテッド | 中枢神経系全体にわたってタンパク質を散在させるための方法および材料 |
| CN111718947B (zh) * | 2020-06-18 | 2022-08-23 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途 |
| WO2023086939A1 (en) * | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
| EP4430201A4 (en) * | 2021-11-12 | 2026-04-08 | Univ Pennsylvania | Gene therapy for the treatment of mucopolysaccharidosis IIIA |
| EP4512892A1 (en) * | 2022-04-19 | 2025-02-26 | JCR Pharmaceuticals Co., Ltd. | Glycoprotein having reduced number of mannose-6-phosphates |
| CN115029360B (zh) * | 2022-05-30 | 2024-08-02 | 上海勉亦生物科技有限公司 | 用于治疗粘多糖贮积症iiia型的转基因表达盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863782A (en) * | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| CA2794196A1 (en) * | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| EP2394667A1 (en) | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| ES2745470T3 (es) | 2011-03-31 | 2020-03-02 | Univ Iowa Res Found | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv |
| US20170191041A1 (en) * | 2014-07-11 | 2017-07-06 | Biostrategies LC | Materials and methods for treating disorders associated with sulfatase enzymes |
-
2018
- 2018-05-11 MX MX2019013528A patent/MX2019013528A/es unknown
- 2018-05-11 RU RU2019140862A patent/RU2019140862A/ru unknown
- 2018-05-11 US US16/611,458 patent/US12221635B2/en active Active
- 2018-05-11 BR BR112019023869A patent/BR112019023869A2/pt unknown
- 2018-05-11 CA CA3061925A patent/CA3061925A1/en active Pending
- 2018-05-11 AU AU2018265869A patent/AU2018265869C1/en active Active
- 2018-05-11 WO PCT/US2018/032454 patent/WO2018209317A1/en not_active Ceased
- 2018-05-11 EP EP18798587.4A patent/EP3622060A4/en active Pending
- 2018-05-11 JP JP2019562293A patent/JP7196099B2/ja active Active
- 2018-05-11 CN CN201880043043.4A patent/CN110809626A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020519629A (ja) | 2020-07-02 |
| JP7196099B2 (ja) | 2022-12-26 |
| AU2018265869A1 (en) | 2019-11-21 |
| CN110809626A (zh) | 2020-02-18 |
| EP3622060A4 (en) | 2021-02-17 |
| CA3061925A1 (en) | 2018-11-15 |
| RU2019140862A3 (https=) | 2021-08-17 |
| AU2018265869B2 (en) | 2024-10-24 |
| US12221635B2 (en) | 2025-02-11 |
| MX2019013528A (es) | 2020-07-14 |
| RU2019140862A (ru) | 2021-06-15 |
| EP3622060A1 (en) | 2020-03-18 |
| WO2018209317A1 (en) | 2018-11-15 |
| US20210324354A1 (en) | 2021-10-21 |
| AU2018265869C1 (en) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019023869A2 (pt) | variantes de sulfamidase (sgsh), vetores, composições e métodos e usos para tratar mucopolissacaridose tipo iiia (mps iiia) | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| BR112019009113A2 (pt) | formulações de vírus adenoassociado | |
| BRPI0911385B8 (pt) | polipeptídeo isolado, polipeptídeo de fusão, multímero e composição farmacêutica | |
| BR112016024379A2 (pt) | variantes ldlr e seu uso em composições para reduzir os níveis de colesterol | |
| CL2017002028A1 (es) | Mejora del suministro de partículas virales al cuerpo estriado y al córtex. | |
| PE20170771A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
| BR112019000098A2 (pt) | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio | |
| BR112019009074A2 (pt) | composições, métodos e uso de transferência genética para o tratamento de doenças neurodegenerativas | |
| UY32607A (es) | Mutantes de fgf21 y usos del mismo | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| BR112014028666A2 (pt) | métodos e composições para o tratamento de depósitos amiloides | |
| BR112019004353A2 (pt) | métodos e vetores para tratar distúrbios do cns | |
| BR112017014615A2 (pt) | proteínas de fusão de multi-direcionamento e seus usos | |
| BR112018011046A2 (pt) | agonistas receptores de piperidinona formil peptí-deo 2 e de formil peptídeo 1 | |
| BR112018009534A2 (pt) | composição farmacêutica contendo 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi }-n-(metilsulfonil)acetamida | |
| CR20200454A (es) | Compuestos agonistas del factor de diferenciación del crecimiento 15 y sus métodos de uso | |
| MX2018014718A (es) | Compuestos y su uso para reducir los niveles de ácido úrico. | |
| BR112017005235A2 (pt) | vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc) | |
| MX2016009630A (es) | Compuestos inmunomoduladores. | |
| BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
| BR112017017970A2 (pt) | composição de fragrância e combinação de fragrâncias | |
| BR112017013999A2 (pt) | ?composição derivada de uma bifidobactéria? | |
| BR112018077225A2 (pt) | proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |